Brief: Endo Announces Agreement For Paladin Labs To Develop And Supply Quoin Pharmaceuticals' Qrx003 In Canada
15/07/2022 15:59
July 15 (Reuters) - Quoin Pharmaceuticals Ltd 2EBy.F :
* ENDO ANNOUNCES AGREEMENT FOR PALADIN LABS TO DEVELOP,
COMMERCIALIZE AND SUPPLY QUOIN PHARMACEUTICALS' QRX003 IN CANADA
* ENDO INTERNATIONAL PLC - PALADIN CURRENTLY EXPECTS TO
LAUNCH
PRODUCT IN 2025 IN CANADA.
Source text for Eikon: ID:nCNW1jDc5a
Further company coverage: 2EBy.F
((reuters.briefs@thomsonreuters.com;))
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes